Eyeing clinical proof-of-concept for HER3 drug, Amgen-partnered biotech scores $125M for precision antibodies

When it comes to redrawing the boundaries of what proteins are druggable, small molecules have soaked up the spotlight. Hordes of new entrants — inhibitors, allosteric modulators, degraders — promise to make a big difference by hitting disease-causing proteins at the right spot.

Over the last five years a biotech out of Singapore has been trying to show that the same approach can be applied to antibodies. Now Novo Holdings is leading a $125 million Series C designed to push them toward clinical proof-of-concept.